Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Forum

    • 16 Accesses

    This is a preview of subscription content, log in to check access.

    References

    Reference

    1. 1.

      Dyer C. US court rules that patients harmed by generic drugs cannot claim damages. BMJ 2011; 342: d4079

    2. 2.

      Taylor L. Genericsmakers have no duty to warn of side effects, US Supreme Court rules. 2011 Jun 24 [online]. Available from URL: http://www.pharmatimes.com [Accessed 2011 Aug 8]

    Reference

    1. 3.

      Mooney H. New NHS board should leave job of commissioning to clinical groups. BMJ 2011; 343: d4367

    2. 4.

      Hawkes N. Field force to oversee commissioning will comprise more than 2000 people, leaked report shows. BMJ 2011; 343: d4433

    Reference

    1. 5.

      European Medicines Agency. European Medicines Agency plans public access to information on side effects. 2011 Jul 8 [online]. Available from URL: http://www.ema.europa.eu [Accessed 2011 Aug 8]

    Reference

    1. 6.

      Health Canada. Adverse reaction and incident reporting — 2010. Canadian Adverse Drug Reaction Newsletter 2011; 21 (3): 2–4

    Reference

    1. 7.

      European Federation of Pharmaceutical Industries and Associations. New study on HTA processes highlights areas for improvement to accelerate patients access to innovative medicines [media release]. 2011 Jul 13 [online]. Available from URL: http://www.efpia.org [Accessed 2011 Aug 9]

    References

    1. 8.

      Roehr B. Vermont moves closer to single payer healthcare financing. BMJ 2011; 343: d4424

    2. 9.

      Hsiao WC, Knight AG, Kappel S, et al. What other states can learn from Vermonts bold experiment: embracing a single-payer health care financing system. Health Affairs 2011; 30: 7: 1231–41

    3. 10.

      Moynihan R. New Zealand agency comes under pressure to pay more for drugs. BMJ 2011; 342: d3933

    Reference

    1. 11.

      Moynihan R. New Zealand agency comes under pressure to pay more for drugs. BMJ 2011; 342: d3933

    References

    1. 12.

      Gerber A, Stock S, Dintsios CM. Reflections on the changing face of German Pharmaceutical Policy: how far is Germany from value-based pricing? Pharmacoeconomics 2011; 29 (7): 549–53

    2. 13.

      Kresge N, Connolly A. A new pricing game for drugmakers in Europe. 2011 Jun 2 [online]. Available from URL: http://www.businessweek.com [Accessed 2011 Aug 10]

    References

    1. 14.

      Kmietowicz Z. Cameron proposes radical changes to England’s NHS reforms. BMJ 2011; 342: d3624

    2. 15.

      Torjesen I. NICE will retain drug approval role in government U turn. BMJ 2011; 342: d3862

    Reference

    1. 16.

      Krauss GL, Caffo B, Chang Y-T, et al. Assessing bioequivalence of generic antiepilepsy drugs. Ann Neurol 2011; 70 (2): 221–8

    Reference

    1. 17.

      Danish Medicines Agency. A review of adverse reaction data for a number of medicines for treatment of dyspepsia and certain types of medicines for treatment of cardiovascular diseases after the reassessment of reimbursement in 2010. Danish Pharmacovigilance Update 2011; 2 (6): 7–10

    Reference

    1. 18.

      Food and Drug Administration. FDA drug safety communication: ongoing safety review of oral osteoporosis drugs (bisphosphonates) and potential increased risk of esophageal cancer. 2011 Jul 22 [online]. Available from URL: http://www.fda.gov [Accessed 2011 Aug 10]

    References

    1. 19.

      Bramness JG. Antidepressants and road traffic accidents. Studies on prescription epidemiology and road traffic incidents [abstract no. 001]. 10th World Congress of Biological Psychiatry; 2011 May 29–Jun 2; Prague [online]. Available from URL: http://www.wfsbp-congress.org [Accessed 2011 Aug 10]

    2. 20.

      Ramaekers J. Differential effects of antidepressants on actual driving performance [abstract no. 004]. 10th World Congress of Biological Psychiatry; 2011 May 29–Jun 2; Prague [online]. Available from URL: http://www.wfsbp-congress.org [Accessed 2011 Aug 10]

    Reference

    1. 21.

      Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council Cognitive Function and Ageing Study. J Am Geriatr Soc. Epub 2011 Jun 24

    Reference

    1. 22.

      Croen LA, Grether JK, Yoshida CK, et al. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. Epub 2011 Jul 4

    References

    1. 23.

      Schmidt M, Christiansen CF, Mehnert F, et al. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ 2011; 343: d3450

    2. 24.

      Gurwitz JH. NSAIDs and atrial fibrillation. BMJ 2011; 343: d2495

    3. 25.

      Vestergaard P, Hermann P, Jensen J-EB, et al. Effects of paracetamol, nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS). Osteoporos Int. Epub 2011 Jun 28

    References

    1. 26.

      Chang CH, Lin JW, Wu LC, et al. Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. JCO 2011; 29 (22): 3001–7

    2. 27.

      FDA. FDA Drug Safety Communication: no increase in risk of cancer with certain blood pressure drugs — Angiotensin Receptor Blockers (ARBs). 2011 Jun 3 [online]. Available from URL: http://www.fda.gov [Accessed 2011 Aug 10]

    References

    1. 28.

      Hanna L. Vasomotor hot flashes and heart rate variability: a placebo-controlled trial of postmenopausal hormone therapy. 13th World Congress on Menopause; 2011 Jun 8–11; Rome [online] Available from URL: http://www.imsroma2011.com [Accessed 2011 Aug 10]

    2. 29.

      Christine MM. Mission study, 3rd follow up: the news results of a French National Cohort on coronary heart disease incidence in postmenopausalwomentreated byHormone Replacement Therapy or not. 13thWorld Congress onMenopause; 2011 Jun 8–11; Rome [online] Available from URL: http://www.imsroma2011.com [Accessed 2011 Aug 10]

    References

    1. 30.

      Schneider BP, Li L, Miller K, et al. Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103 [abstract no. 1000]. 47th Annual Meeting of the American Society of Clinical Oncology; 2011 Jun 3–7; Chicago (IL) [online]. Available from URL: http://www.asco.org [Accessed 2011 Aug 10]

    2. 31.

      American Society of Clinical Oncology. Predictive biomarker for taxane-induced neuropathy identified (cited in ASCO Daily News — Section A). 2011 Jun 6 [online]. Available from URL: http://chicago2011.asco.org [Accessed 2011 Aug 10]

    3. 32.

      Yardley DA, Hainsworth JD, Harwin WN, et al. TITAN: Ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple-negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial [abstract no. 1103]. 47th Annual Meeting of the American Society of Clinical Oncology; 2011 Jun 3–7; Chicago (IL) [online]. Available from URL: http://www.asco.org [Accessed 2011 Aug 10]

    4. 33.

      Inno A, Strippoli A, Nazzicone G, et al. Treatment of HER2-negative metastatic breast cancer (MBC) with bevacizumab (BEV) plus paclitaxel (TXL): a single-center phase II study [abstract no. e11509]. 47th Annual Meeting of the American Society of Clinical Oncology; 2011 Jun 3–7; Chicago (IL) [online]. Available from URL: http://www.asco.org [Accessed 2011 Aug 10]

    5. 34.

      Domchek SM, Friebel T, Neuhausen SL, et al. Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer? [abstract no. 1501]. 47th Annual Meeting of the American Society of Clinical Oncology; 2011 Jun 3–7; Chicago (IL) [online]. Available from URL: http://www.asco.org [Accessed 2011 Aug 10]

    6. 35.

      American Society of Clinical Oncology. Study suggests no increased breast cancer risk with hormone replacement therapy after risk-reducing salpingo-oophorectomy (cited in ASCO Daily News Wrap-Up Edition). 2011 Jun 11 [online]. Available from URL: http://chicago2011.asco.org [Accessed 2011 Aug 10]

    7. 36.

      Goss PE, Ingle JN, Ales-Martinez J, et al. Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3: a randomized, placebo-controlled clinical trial [abstract no. LBA504]. 47th Annual Meeting of the American Society of Clinical Oncology; 2011 Jun 3–7; Chicago (IL) [online]. Available from URL: http://www.asco.org [Accessed 2011 Aug 10]

    8. 37.

      Crook JM, O’Callaghan CJ, Ding K, et al. A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013) [abstract no. 4514]. 47th Annual Meeting of the American Society of Clinical Oncology; 2011 Jun 3–7; Chicago (IL) [online]. Available from URL: http://www.asco.org [Accessed 2011 Aug 10]

    9. 38.

      American Society of Clinical Oncology. Intermittent androgen suppression noninferiority could change treatment of localized prostate cancer [abstract 4514]. ASCO Daily News, 3–7 June 2011; Chicago (IL) [online]. Available from URL: http://chicago2011.asco.org/ASCODailyNews/Abstract4514.aspx [Accessed 2011 Aug 31]

    References

    1. 39.

      Xu Z, Niu W. Evaluating the long-term cost-effectiveness of tight glycaemic control in patients with type 2 diabetes in China: amodeling study of long-term costs and health outcomes [abstract no. 0898-P]. 71st Annual Scientific Sessions of the American Diabetes Association; 2011 Jun 24–28; San Diego (CA) [online]. Available from URL: http://professional.diabetes.org [Accessed 2011 Aug 10]

    2. 40.

      Chen S-Y, Kovacs B, Stokes M, et al. Clinical and economic outcomes of appropriate oral antidiabetic drug (OAD) treatment among type 2 diabetes mellitus (T2DM) patients with chronic kidney disease (CKD) [abstract no. 0052-LB]. 71st Annual Scientific Sessions of the American Diabetes Association; 2011 Jun 24–28; San Diego (CA) [online]. Available from URL: http://professional.diabetes.org [Accessed 2011 Aug 10]

    3. 41.

      Zhang Y, Hogan P. Cost effectiveness of a human fibroblast-derived dermal substitute for the treatment of diabetic foot ulcers in Medicare and commercially insured populations [abstract no. 0053-LB]. 71st Annual Scientific Sessions of the American Diabetes Association; 2011 Jun 24–28; San Diego (CA) [online]. Available from URL: http://professional.diabetes.org [Accessed 2011 Aug 10]

    4. 42.

      Bergenheim K, Williams SA, Bergeson JG, et al. Cost-effectiveness of saxagliptin in type 2 diabetes in the United States [abstract no. 2369-PO]. 71st Annual Scientific Sessions of the American Diabetes Association; 2011 Jun 24–28; San Diego (CA) [online]. Available from URL: http://professional.diabetes.org [Accessed 2011 Aug 10]

    5. 43.

      Pollock R, Curtis B, Smith H, et al. Estimating the Long-term cost-effectiveness of premixed insulin analogs versus long-acting analog insulin in the US [abstract no. 0418-PP]. 71st Annual Scientific Sessions of the American Diabetes Association; 2011 Jun 24–28; San Diego (CA) [online]. Available from URL: http://professional.diabetes.org [Accessed 2011 Aug 10]

    6. 44.

      Herman WH, Edelstein SL, Ratner RE, et al. The 10-year cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetesmellitus: an intentto- treat analysis of diabetes prevention [abstract no. 0136-LBOR]. 71st Annual Scientific Sessions of the American Diabetes Association; 2011 Jun 24–28; San Diego (CA) [online]. Available from URL: http://professional.diabetes.org [Accessed 2011 Aug 10]

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Forum. Pharm Med 25, 331–342 (2011). https://doi.org/10.1007/BF03256875

    Download citation